1) Lilly
happily rings in a new drug…Cymbalta… as FDA approves it.
As the second
drug in the SNRI class of antidepressants it does offer
additional hope to those who suffer from depression. Both
serotonin and norepinephrine, two neurotransmitters, are
increased. Lilly's original drug, Prozac, only increased
serotonin. Some think that this drug will lift Lilly out of the
depression felt when Prozac lost patent…. it couldn't hurt! Now
comes the odd part….While does not yet have the FDA nod, it
could also soon be approved for urinary incontinence. If you
happen to have both….this could be the drug for you! (Stay tuned
on that one!)
http://news.moneycentral.msn.com/ticker/article.asp?Feed=RTR&Date=20040804&ID=3886537&Symbol=US:LLY
2) The
cost of depression?
Want to know
how much depression costs your organization? Follow this link to
a site that will use your populations
age and gender
distribution for 3 groups:age 18-44, 45-54 and 55+. (You can use
the defaults if you don't know). Have your population's average
daily wage handy (or an estimate). The other questions should be
easy (you will pick your industry type from a list)
One 70,00
employee financial institution would have a benefit of between
$4,653,303 and $8,748,209 from treating depression. (Increase in
productivity and reduction in direct medical costs of $1.5
million to $2.2 million)
Go ahead….what
do you have to loose?
http://www.phrma.org/publications/policy/07.06.2005.1014.cfm
3) Happy
on the wings of a DOV….
Merck
licenses a new antidepressant compound from DOV pharmaceuticals.
In today's market climate it may cost less for a one
pharmaceutical company to buy another WHO:E company than to by
parts of the pipeline. Time will tell if this will be a
profitable deal.
http://biz.yahoo.com/rc/040805/health_merck_dov_2.html
4) Put on
a happy face… even if you have AIDS.
Sculptra is
now an FDA approved face putty. It is used when patients become
gaunt looking. Originally approved for AIDS wasting it will
likely find a use in the cosmetic cabinet of non-aids patients.
It is expected to be marketed in the 3rd quarter so we have some
time to develop strategies to avoid misuse? PA anyone?
http://www.pharmacyonesource.com/members/work/daily_news/article.asp?category_id=5&record_id=115427